Select Page

PURA – Puration To Produce CBD Beverages In Europe Targeting $17 Billion Market Opportunity

PURA – Puration To Produce CBD Beverages In Europe Targeting $17 Billion Market Opportunity

PURA introduced its first CBD beverage, EVERx CBD Sports Water over two years ago breaking $1 million in sales for the first time last year in 2018.

DALLAS, Nov. 05, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE – Puration, Inc. (USOTC: PURA) today announced plans to begin producing CBD beverages in Europe. 

PURA introduced its first CBD beverage, EVERx CBD Sports Water over two years ago breaking $1 million in sales for the first time last year in 2018.

PURA reported $1 million in sales in the first six months of this year, 2019.  A recent analyst review of PURA projected the company reaching $8 million in revenue in 2020.  PURA recently announced a distribution agreement in Europe for its EVERx CBD Sports Water with other CBD infused beverages to follow.

The initial agreement is estimated to add $4 million in sales next year.  Management indicates that the potential of European distribution beyond the initial $4 million projection warrants the establishment of a local bottling capacity.  The European market for CBD is projected to reach nearly US $17 billion by 2023.

Yesterday, PURA announced executing a letter of intent to acquire a company headquartered in Germany as part of a strategy to bottle PURA’s CBD infused beverages locally.  PURA management anticipates the acquisition can be completed by the end of next week. 

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Leave a Reply

avatar

Join Our Newsletter

Get stock alerts, news & related alerts straight to your inbox!